When will coronavirus vaccines be given to children under 3 years of age?

Children under 3 years of age are not eligible for COVID-19 vaccination in Argentina . Even in the United States, people under 5 years of age The Pfizer-BioNTech laboratory is the first laboratory in North America to receive COVID-19 vaccine approval for people over 5 years of age.And the Sinopharm vaccine broadens margins and allows people over 3 years of age to be vaccinated.

But what will happen to the newborn population between 3 and 5 years of age, depending on where the newborn is in the world or the vaccine being vaccinated? In fact, it is the population most relegated against the SARS-CoV-2 coronavirus, since there is still no vaccine in this age group.

In the United States, two state-of-the-art COVID-19 vaccination laboratories, Moderna and Pfizer, have been working on the correct formula for vaccinating this group of children for months, and some scientists hope to discover it. “Goldilocks” defines it as a dose. powerful enough to provide lasting protection, but it is not enough to worry about a wide range of side effects such as high fever.

For children under 6 years of age, Moderna tested a two-dose regimen with a quarter of the adult dose. Next month, Pfizer is expected to seek approval for three prick treatments in children under 5 years of age, with 1/10 higher doses for those over 11 years of age.Moderna is also expected to publish clinical trial data in the next age range between 6 and 11 years of age in the near future.

Yvonne Maldonado, professor of pediatric infectious diseases at Stanford University and one of the leading researchers at Pfizer's Pediatric Vaccine Testing Center, said that in the coming weeks the data provided by Moderna and BionTech will be effective. The scientist pointed out that the researchers were investigating whether Moderna, who took more Moderna, “produces a stronger immune response” for young children than Pfizer achieved.

Moderna's choice attracted the attention of federal scientists and vaccine experts. A series of studies raised questions about Pfizer's lack of vaccine protection time in school-age children.

Ofer Levy, a pediatric expert at Harvard Medical School and a member of the Food and Drug Administration (FDA) Independent Vaccine Advisory Committee, explains that Pfizer may have chosen a dose that is too low for children between 5 and 11 years of age. Maximizing safety is our top priority. To date, this laboratory is the only laboratory in the United States that has approved the vaccination of children between the ages of 5 and 11. Received.Adult permission applies to guests aged 16 and 17.

Moderna approved the vaccination of adolescents in June, but the FDA postponed the review of applications due to concerns about the risk of myocarditis. Concerns about the risk of myocarditis caused myocarditis inflammation and are associated with Moderna and Pfizer vaccines. Currently, in the United States, more than 22 million people under 18 are scheduled to receive the Pfizer vaccine, but demand has stabilized.For example, only 1 in 4 children between 5 and 11 years of age received a complete schedule, but the vaccine has stabilized. It has been administered to this group for more than 4 months.

However, as more and more people across the country stop wearing masks, more and more parents have returned to work, and as the summer travel season approaches, there is still a demand for the protection of young children. “There is no doubt that effective vaccines benefit children less than adults,” said Eric Rubin, an infectious disease expert at the TH Chan School of Public Health at Harvard University and a member of the FDA Advisory Committee.

In Argentina, COVID-19 vaccination began last October due to the application of the Chinese Sinoparm vaccine. According to data from the Public Immunization Monitor, more than 8.7 million children between the ages of 3 and 11 were vaccinated. More than 575,000 children have associated risk factors.

In recent weeks, the Argentine Association of Pediatrics and the Federal Health Commission have held meetings to promote vaccination against other vaccines included in the official mandatory immunization schedule, as well as COVID-19 vaccination.

On January 20, the U.S. Department of Medicines, Food and Medical Technology (ANMAT) approved the use of the COVID-19 vaccine from the Pfizer/BioNTech Research Institute for children aged 5 to 11 years. And last Saturday, the Ministry of Health announced the expansion of the Moderna vaccine for children between 6 and 11 years of age. This decision is based on an analysis by the National Institute of Medicines (part of ANMAT) and clinical evidence demonstrates applicability. Technical guidelines for the use of this vaccine in this age group will be established in the future.

Experts say they need a vaccine.

(CDC) 336코로나19 .

Hope for early coverage of young children has increased after regulators pressured Pfizer-Biontech last month to publish preliminary results from a three-time vaccination trial. The FDA wanted to start a vaccination campaign with two doses while waiting for the final result of the third dose. However, these efforts ended with Pfizer's new data covering information related to the Omicron wave convincingly proving that both doses were not sufficiently protected against symptomatic infections.

Now, at about the same time, more detailed results are being produced for Pfizer and Moderna tests. It is not yet known whether the vaccine is effective enough for the younger age group, but studies say they are both safe.

Paul Burton, Chief Medical Officer of Moderna, said: “I have not seen anything inappropriate so far, and I have confidence in the safety profile.Pfizer spokesman Amy Rose noted that after extensive research, the Pfizer-BioNTech companies have chosen “the safest and most tolerable dose” for young children.Federal authorities say the effectiveness of the Pfizer vaccine and the Moderna vaccine decreases over time. Some studies in adults have shown that Moderna's protection lasts longer.

Keep reading:

ANMAT approved the use of the Pfizer vaccine for children between the ages of 5 and 11.